The 8 most recent market catalysts affecting $HQY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on HealthEquity, Raises Price Target to $115
This filing indicates that Barclays analyst Peter Warendorf has maintained an 'Overweight' rating on HealthEquity (HQY) and raised the price target from $110 to $115. This action s…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $142
Deutsche Bank analyst George Hill maintained a 'Buy' rating on HealthEquity (HQY) and raised the price target from $135 to $142. This action indicates a positive outlook from a pro…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on HealthEquity, Maintains $115 Price Target
This 8-K filing discloses that BTIG analyst David Larsen has reiterated a 'Buy' rating on HealthEquity (HQY) and maintained a $115 price target. This action signals continued confi…
Aug 27, 2026
Corporate Catalyst
Bearish
Impact 75
HealthEquity shares are trading lower after the company issued Q2 financial results. The company affirmed its FY27 adjusted EPS guidance with its midpoint below estimates.
The primary impact here is on HealthEquity (HQY) due to the direct corporate news. The reaffirmation of FY27 adjusted EPS guidance with a midpoint below estimates signals a potenti…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 92
HealthEquity Q2 Adj. EPS $1.24 Beats $1.19 Estimate, Sales $350.732M Beat $349.248M Estimate
HealthEquity announced its Q2 earnings, reporting an adjusted EPS of $1.24, which exceeded the analyst consensus of $1.19 by 4.2%. Sales also beat estimates, coming in at $350.732 …
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 65
HealthEquity Affirms FY2027 Adj EPS Guidance of $4.66-$4.73 vs $4.72 Est; Raises FY2027 Sales Guidance from $1.410B-$1.420B to $1.411B-$1.421B vs $1.416B Est
HealthEquity (HQY) has released an 8-K filing affirming its FY2027 Adjusted EPS guidance and slightly raising its FY2027 sales outlook. The EPS guidance remains unchanged, aligning…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
HealthEquity Raises FY2027 GAAP EPS Guidance from $2.88-$2.95 to $2.88-$2.96 vs $2.94 Est
HealthEquity (HQY) has raised its FY2027 GAAP EPS guidance from a range of $2.88-$2.95 to $2.88-$2.96. While the lower bound remains unchanged, the slight increase in the upper bou…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on HealthEquity, Raises Price Target to $115
BTIG analyst David Larsen maintained a 'Buy' rating on HealthEquity (HQY) and raised the price target from $110 to $115. This action signals continued confidence from a prominent a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.